Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded
- Contract number
- SPE2DR26FJUS7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $17,474
Award facts
- Contract value 100% obligated
- $17,474.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,474.40 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml autoinjector units. This firm fixed-price delivery order, issued on November 17, 2025, is structured as a standard delivery against DMS Pharmaceutical Group's broader Indefinite Delivery Contract (IDC) with the DLA. The contract contains no set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. The ultimate completion date for this delivery order is December 9, 2025, with performance to occur at the contractor's facility in Park Ridge, Illinois.
This delivery order is issued under DMS Pharmaceutical Group's single-award IDC established through the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide comprehensive pharmaceutical support to Department of Defense healthcare facilities worldwide. The parent contract, valued at $499,999,999 and awarded on November 13, 2025, extends through December 31, 2036, with a 30-month base period and three 30-month option periods. DMS Pharmaceutical Group's established track record supplying specialized biologics, immunosuppressants, and other critical pharmaceutical products positions the company as a key regional prime vendor contractor supporting the military's diverse and specialized medical supply requirements globally.
Quick answers
Who was awarded contract SPE2DR26FJUS7?
SPE2DR26FJUS7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 17, 2025.
How much is contract SPE2DR26FJUS7 worth?
The government has obligated $17,474 on SPE2DR26FJUS7.
Is contract SPE2DR26FJUS7 an order under another contract?
Yes. SPE2DR26FJUS7 is a delivery order under SPE2DR25D9329, an indefinite delivery contract.
Was contract SPE2DR26FJUS7 competed?
The extent of competition for SPE2DR26FJUS7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award